Literature DB >> 26981941

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.

Pantelis A Sarafidis1, Apostolos Tsapas1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 26981941     DOI： 10.1056/NEJMc1600827

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  12 in total

1.  Empagliflozin reduces blood pressure and uric acid in patients with type 2 diabetes mellitus: a systematic review and meta-analysis.

Authors:  Di Zhao; Hui Liu; Pingshuan Dong
Journal:  J Hum Hypertens       Date:  2018-11-15       Impact factor: 3.012

Review 2.  Blood pressure reduction in diabetes: lessons from ACCORD, SPRINT and EMPA-REG OUTCOME.

Authors:  Pantelis A Sarafidis; Antonios A Lazaridis; Gema Ruiz-Hurtado; Luis M Ruilope
Journal:  Nat Rev Endocrinol       Date:  2017-01-20       Impact factor: 43.330

Review 3.  Potential Use of SGLT-2 Inhibitors in Obstructive Sleep Apnea: A new treatment on the horizon.

Authors:  Cem Tanriover; Duygu Ucku; Merve Akyol; Enes Cevik; Asiye Kanbay; Vikas S Sridhar; David Z I Cherney; Mehmet Kanbay
Journal:  Sleep Breath       Date:  2022-04-04       Impact factor: 2.816

4.  Bibliometric Study of Sodium Glucose Cotransporter 2 Inhibitors in Cardiovascular Research.

Authors:  Lu Chen; Siyuan Ma; Donghong Hu; Hairuo Lin; Yingqi Zhu; Kaitong Chen; Lin Chen; Cankun Zheng; Jichen Liu; Yulin Liao
Journal:  Front Pharmacol       Date:  2020-09-15       Impact factor: 5.810

Review 5.  The optimal blood pressure target in diabetes mellitus: a quest coming to an end?

Authors:  Eirini Papadopoulou; Elena Angeloudi; Spiridon Karras; Pantelis Sarafidis
Journal:  J Hum Hypertens       Date:  2018-06-22       Impact factor: 3.012

6.  Sodium-Glucose Co-transporter 2 (SGLT2) Inhibitor: Comparing Trial Data and Real-World Use.

Authors:  Andrew McGovern; Michael Feher; Neil Munro; Simon de Lusignan
Journal:  Diabetes Ther       Date:  2017-03-21       Impact factor: 2.945

Review 7.  SGLT-2 Inhibitors and Cardiovascular Protection: Lessons and Gaps in Understanding the Current Outcome Trials and Possible Benefits of Combining SGLT-2 Inhibitors With GLP-1 Agonists.

Authors:  Elamin Abdelgadir; Fauzia Rashid; Alaaeldin Bashier; Razan Ali
Journal:  J Clin Med Res       Date:  2018-06-27

8.  Endothelin receptor antagonists for the treatment of diabetic nephropathy: A meta-analysis and systematic review.

Authors:  Li Zhang; Shuai Xue; Jie Hou; Guang Chen; Zhong-Gao Xu
Journal:  World J Diabetes       Date:  2020-11-15

9.  Empagliflozin ameliorates symptoms of diabetes and renal tubular dysfunction in a rat model of diabetes with enlarged kidney (DEK).

Authors:  Ayaka Domon; Kentaro Katayama; Touko Sato; Yuki Tochigi; Hiroyuki Tazaki; Hiroetsu Suzuki
Journal:  PLoS One       Date:  2021-05-04       Impact factor: 3.240

10.  Characterization of the renal cortical transcriptome following Roux-en-Y gastric bypass surgery in experimental diabetic kidney disease.

Authors:  Meera Nair; William P Martin; Vadim Zhernovkov; Jessie A Elliott; Naomi Fearon; Hans Eckhardt; Janet McCormack; Catherine Godson; Eoin Patrick Brennan; Lars Fandriks; Neil G Docherty; Carel W le Roux
Journal:  BMJ Open Diabetes Res Care       Date:  2020-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.